Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
MET inhibitor
Asia
BMS-Eisai, China price cuts, AZ-Hutchmed—Fierce Pharma Asia
BMS and Eisai form ADC alliance. AZ and Bayer lose tenders for key meds in China's latest VBP. Hutchmed and AZ win China go-ahead for a MET inhibitor.
Angus Liu
Jun 25, 2021 10:50am
AZ, HutchMed get China nod for Orpathys for rare type of NSCLC
Jun 23, 2021 11:17am
Merck KGaA matches Novartis with FDA green light for Tepmetko
Feb 4, 2021 12:09pm
Next-gen kinase inhibitors amp up cancer attacks—and M&A, too
Sep 17, 2020 8:45am
Novartis beats out Merck KGaA with lung cancer drug Tabrecta
May 6, 2020 3:07pm
Merck KGaA bags targeted lung cancer nod for Tepmetko in Japan
Mar 25, 2020 11:15am
